Illimis Therapeutics
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18 Heolleung-ro 569-gil, Seoul, 06376, S...Phone Number
+82 24456877Website
www.illimistx.comRevenue
$11.8 MillionIndustry
About Illimis Therapeutics
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.Explore more
Illimis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Illimis Therapeutics Tech Stack
A closer look at the technologies used by Illimis Therapeutics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Illimis Therapeutics
Sign Up For FreeTo access detailed company insights
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from e... Read More
